Market Estimates
Valuation Metrics
Financials
Trading Trends
SLRX News & Events
Events Timeline
No data
News
![an image of [object Object]](/_next/image?url=https%3A%2F%2Fd5bp8bijhhba2.cloudfront.net%2Fimage%2Fcover_image%2F20260105180320_6942ea89bd01bfb6f9f13aeb0aeba69f.jpeg&w=384&q=75)
![an image of [object Object]](/_next/image?url=https%3A%2F%2Fd5bp8bijhhba2.cloudfront.net%2Fimage%2Fdefault_image%2Fnewsfilter.png&w=384&q=75)
![an image of [object Object]](/_next/image?url=https%3A%2F%2Fd5bp8bijhhba2.cloudfront.net%2Fimage%2Fcover_image%2F20251220002239_78df02ea0f792a5d1d68e2e7304e0064.jpeg&w=384&q=75)
People Also Watch
Frequently Asked Questions
What is Salarius Pharmaceuticals Inc (SLRX) stock price today?
The current price of SLRX is 0.8225 USD — it has increased 26.62 % in the last trading day.
What is Salarius Pharmaceuticals Inc (SLRX)'s business?
Salarius Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on advancing its pipeline of peptide conjugate therapeutics engineered through its IMP3ACT platform that reduces the complexity of drug development and manufacturing. It is focused on developing effective treatments for patients with cancer with high, unmet medical needs. The company’s lead candidate, seclidemstat (SP-2577), is being studied as treatment for pediatric cancers, sarcomas, and other cancers with limited treatment options. Its pipeline consists of SP-3164 a targeted protein degrader and seclidemstat (SP-2577), a targeted protein inhibitor. SP-3164 is a next-generation cereblon-binding MG. SP-2577 is a small-molecule LSD1 inhibitor with a novel scaffold.
What is the price predicton of SLRX Stock?
Wall Street analysts forecast SLRX stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for SLRX is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
What is Salarius Pharmaceuticals Inc (SLRX)'s revenue for the last quarter?
Salarius Pharmaceuticals Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.
What is Salarius Pharmaceuticals Inc (SLRX)'s earnings per share (EPS) for the last quarter?
Salarius Pharmaceuticals Inc. EPS for the last quarter amounts to -1.81 USD, decreased -84.09 % YoY.
What changes have occurred in the market's expectations for Salarius Pharmaceuticals Inc (SLRX)'s fundamentals?
How many employees does Salarius Pharmaceuticals Inc (SLRX). have?
Salarius Pharmaceuticals Inc (SLRX) has 2 emplpoyees as of January 07 2026.
What is Salarius Pharmaceuticals Inc (SLRX) market cap?
Today SLRX has the market capitalization of 4.20M USD.